CTI BioPharma Corp. (DE) Common Stock
CTIC
CTIC was delisted on the 23rd of June, 2023.
93 hedge funds and large institutions have $152M invested in CTI BioPharma Corp. (DE) Common Stock in 2014 Q1 according to their latest regulatory filings, with 25 funds opening new positions, 34 increasing their positions, 20 reducing their positions, and 8 closing their positions.
213% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 8
138% more capital invested
Capital invested by funds: $63.9M → $152M (+$88M)
70% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 20
22% more funds holding
Funds holding: 76 → 93 (+17)
73% less call options, than puts
Call options by funds: $2.32M | Put options by funds: $8.66M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$23M |
| 2 |
State Street
Boston,
Massachusetts
|
+$16.5M |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$4.62M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.27M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$3.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.95M |
| 2 |
PA
Perceptive Advisors
New York
|
-$7.13M |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$2.34M |
| 4 |
D.E. Shaw & Co
New York
|
-$1.42M |
| 5 |
Goldman Sachs
New York
|
-$1.37M |
CTIC Hedge Fund Activity: Q1 2014 in Review
93 of the 3,475 institutional investors tracked by Wall St. Rank reported a position in CTI BioPharma Corp. (DE) Common Stock (CTIC) for Q1 2014, worth a combined $152M — up 138% from $63.9M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new CTIC positions and 8 closed out — a net gain of 17 holders — while 34 added to existing stakes and 20 trimmed.
The largest buyer was Eagle Asset Management, opening a new position worth an estimated $23M. The largest seller was Fidelity Investments, cutting an estimated $8.95M.
- 93 institutional investors held CTI BioPharma Corp. (DE) Common Stock (CTIC) as of Q1 2014, up from 76 in Q4 2013.
- Funds reported $152M of CTI BioPharma Corp. (DE) Common Stock stock for Q1 2014, up 138% quarter-over-quarter.
- 25 funds opened new CTI BioPharma Corp. (DE) Common Stock positions in Q1 2014 and 8 closed out, a net change of +17 holders.
- The largest CTI BioPharma Corp. (DE) Common Stock buyer in Q1 2014 was Eagle Asset Management, an estimated $23M added.
- The largest CTI BioPharma Corp. (DE) Common Stock seller in Q1 2014 was Fidelity Investments, an estimated $8.95M sold.
Based on aggregated 13F filings for Q1 2014.